Navigation Links
Sangamo BioSciences to Acquire Ceregene
Date:8/26/2013

AAV to produce a steady supply of NGF in a specific area of the brain, the treatment is designed to address the loss of cholinergic neurons which is associated with memory loss and cognitive decline in AD. The trial is fully enrolled and the subjects, half of whom were treated with CERE-110 and half with sham surgery (placebo), are in the follow-up stage of the study which will evaluate the effect of treatment on established clinical end-points in cognitive function and quality of life.   The results of this trial are expected in 2015. 

"Over 5 million people in the U.S. live with Alzheimer's, which is a devastating disease for both patients and their families, and more effective treatment options are needed," stated Geoff Nichol, M.B. Ch.B., Sangamo's executive vice president of research and development. "Early data from the CERE-110 program are encouraging. Clinical data from a Phase 1 study demonstrate that CERE-110 can be safely injected into a specific area of the brain and preclinical studies suggest that treatment can produce levels of NGF that protect cholinergic neurons.  The award granted by the NIH to fund the Phase 2 trial, and participation of the ADCS, a pre-eminent research consortium for testing new treatments for Alzheimer's, demonstrate strong support for the  development of this novel therapeutic."

Conference Call Tomorrow
Sangamo will host a teleconference and webcast tomorrow, Tuesday, August 27, 2013, at 8:30 a.m. ET, to discuss the acquisition and provide a general business overview.  The live webcast can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. A replay of the webcast will also be available for two weeks after the call.

The call will be open to the public: dial-in numbers are 877-377-7
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
2. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
3. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
4. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
5. Sangamo BioSciences Reports First Quarter 2013 Financial Results
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
9. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
10. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
11. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  QB3@953—a San ... University of California (UC) research institute and biotech ... GSK to identify and facilitate collaborations to translate ... patients. The agreement formalizes a relationship ... (DPAc) team and creates a new channel for ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... Chief Executive Officer, will present a corporate overview and business ... New York City . , 22 ... 11:30 am ET at the Millennium Broadway Hotel. , ... pm ET at the St. Regis Hotel. To ...
(Date:8/26/2015)... , Aug. 26, 2015 The North ... witness a CAGR of 7.8% during the forecast period, ... ophthalmology cataract surgery devices market in 2014 and accounted ... ophthalmology cataract surgery devices market is expected to witness ... the increasing strategic expansion of the companies and continuous ...
Breaking Medicine Technology:QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2SciClone To Present At Two Investor Conferences On September 10, 2015 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 3
... 14 Solta Medical, Inc. (Nasdaq: SLTM ), the pioneer ... announced it has received FDA 510(k) clearance for the new ... Fraxel re:store Dual system takes the industry leading ... 1927 nm wavelength, the first ever application of a Thulium laser ...
... 14 Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... tender offer for a portion of its outstanding 2.875% Senior ... "Modified Dutch Auction" procedure, Par is offering to purchase, for ... up to approximately 82.7%, of the outstanding convertible notes, at ...
Cached Medicine Technology:Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 2Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 2Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 4
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading provider ... content is ICD-10 ready and available to all clients. All Krames Patient Education ... which are more targeted and return a more comprehensive data set of content ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... its partnership with Julia Glushko, professional Tennis player for Israel in the Women’s ... Zensah® Compression for all her training and recovery. , With a focus on ...
(Date:8/27/2015)... ... 2015 , ... In addition to its existing Doctor of Philosophy in Leadership ... at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor ... practice nurses for the highest level of clinical nursing practice. , “Our vision ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... -- A new research study conducted by an international team ... including evidence-based guidelines for lower-risk use - to reduce the ... Led by CAMH scientist and CIHR/PHAC* Chair in Applied ... study is being published in the September/October 2011 issue of ...
... of medicines commonly given for pain -- were associated with ... adults, aged 65 to 94, e-published in advance of publication ... The study from researchers at Group Health Research Institute and ... are drugs generally given for insomnia and anxiety, did not ...
... , THURSDAY, Sept. 22 (HealthDay News) -- There ... and other recreational water in the United States in ... to two federal reports released Thursday. The 134 ... and December 2008 occurred in 38 states and Puerto ...
... HealthDay Reporter , THURSDAY, Sept. 22 (HealthDay News) -- ... prostate biopsy are hospitalized within 30 days of the procedure, ... of similarly aged men who do not get prostate biopsies can ... issue of the Journal of Urology . "The overall ...
... By Steven Reinberg HealthDay Reporter , ... containing chloroflouorocarbons (CFCs), which can damage the ozone layer, ... the U.S. Food and Drug Administration announced Thursday. ... Armstrong Pharmaceutical Inc., because it is the only inhaler ...
... of Kentucky,s Dr. Susanne Arnold and colleagues were awarded a ... reasons for the high lung cancer rates in Eastern Kentucky. ... the study began on Sept. 15. Kentucky has the ... the southeastern portion of the state those in the ...
Cached Medicine News:Health News:New study proposes public health guidelines to reduce the harms from cannabis use 2Health News:New study proposes public health guidelines to reduce the harms from cannabis use 3Health News:Opioids linked to higher risk of pneumonia in older adults 2Health News:Infections Linked to Swimming, Drinking Water: CDC 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 3Health News:Asthma Inhaler Primatene Mist Going Off the Market 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 3
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... The Blue Line UNO Splint fits small, medium, ... cushioned two-part design includes both dorsal and volar ... extension. Recommended for those experiencing symptoms of Carpal ... for busy clinics - stock one splint to ...
Comfort Wrist Immobilizer with thumb abduction. 8"L, soft, padded comfort-type wrist immobilizer with dorsal metal stay. The thumb is held in abduction and splintered with a short metal stay....
Medicine Products: